<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Samsung Biologics Co., Ltd. — News on 6ix</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd</link>
<description>Latest news and press releases for Samsung Biologics Co., Ltd. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 20 May 2026 05:05:15 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/samsung-biologics-co-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68362e3578dffbe2df146bf7.webp</url>
<title>Samsung Biologics Co., Ltd.</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd</link>
</image>
<item>
<title>Samsung Biologics : 2025 FY Audited Financial Statements (Consolidated)</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-2025-fy-audited-financial-statements-consolidated</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-2025-fy-audited-financial-statements-consolidated</guid>
<pubDate>Wed, 20 May 2026 05:05:15 GMT</pubDate>
<description>Samsung Biologics : 2025 FY Audited Financial Statements</description>
</item>
<item>
<title>Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/cartography-biosciences-announces-strategic-investment-from-samsung-ventures-to-advance-oncology-pipeline-2</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/cartography-biosciences-announces-strategic-investment-from-samsung-ventures-to-advance-oncology-pipeline-2</guid>
<pubDate>Wed, 06 May 2026 23:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif. & SEOUL, South Korea, May 06, 2026--Cartography Biosciences and Samsung Ventures today announced a strategic investment to support the advancement of Cartography’s differentiated oncology pipeline and expand its proprietary drug discovery platform.</description>
</item>
<item>
<title>Samsung Biologics Listed on Dow Jones Best-in-Class World Index for Fifth Consecutive Year</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-listed-on-dow-jones-best-in-class-world-index-for-fifth-consecutive-year</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-listed-on-dow-jones-best-in-class-world-index-for-fifth-consecutive-year</guid>
<pubDate>Tue, 05 May 2026 11:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has been included in the Dow Jones Best-in-Class World Index (formerly the Dow Jones Sustainability Index) for the fifth consecutive year, reaffirming the company's continued commitment to sustainable growth and responsible business practices.</description>
</item>
<item>
<title>Samsung Biologics Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 22 Apr 2026 06:50:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the first quarter of fiscal year 2026.</description>
</item>
<item>
<title>Samsung Biologics completes acquisition of GSK's manufacturing facility in Rockville, Maryland</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-completes-acquisition-of-gsks-manufacturing-facility-in-rockville-maryland</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-completes-acquisition-of-gsks-manufacturing-facility-in-rockville-maryland</guid>
<pubDate>Tue, 31 Mar 2026 14:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company's first manufacturing presence in the United States.</description>
</item>
<item>
<title>Samsung Biologics Recognized for Advancing Sustainability at 2026 CDMO Leadership Awards</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-for-advancing-sustainability-at-2026-cdmo-leadership-awards</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-for-advancing-sustainability-at-2026-cdmo-leadership-awards</guid>
<pubDate>Thu, 26 Mar 2026 12:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), received recognition at the 2026 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect. The company was awarded the Sustainability Leadership Award, a jury-selected distinction recognizing efforts to advance sustainable practices across its operations and value chain. Samsung Biologics was also named "Best in Class" in Cultural Fit in the 'Biologics—Large CDMOs' cate</description>
</item>
<item>
<title>Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/rapid-micro-biosystems-announces-follow-on-multi-system-order-from-samsung-biologics-to-expand-deployment-of-growth-directr-platform-1</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/rapid-micro-biosystems-announces-follow-on-multi-system-order-from-samsung-biologics-to-expand-deployment-of-growth-directr-platform-1</guid>
<pubDate>Thu, 12 Mar 2026 10:30:00 GMT</pubDate>
<description>Companies deepen partnership to advance automated, integrated microbiology quality controlLEXINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced a new multi-system order from Samsung Biologics for its Growth Direct platform. This follow-on o</description>
</item>
<item>
<title>Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs Site in Korea</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-announces-collaboration-with-lilly-to-establish-new-gateway-labs-site-in-korea-2</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-announces-collaboration-with-lilly-to-establish-new-gateway-labs-site-in-korea-2</guid>
<pubDate>Tue, 10 Mar 2026 11:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced a collaboration agreement with Eli Lilly and Company (Lilly) to establish a Lilly Gateway Labs (LGL) site in Korea.</description>
</item>
<item>
<title>Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-leads-climate-transparency-with-independent-validation-of-product-carbon-footprint-system</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-leads-climate-transparency-with-independent-validation-of-product-carbon-footprint-system</guid>
<pubDate>Fri, 06 Feb 2026 13:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards.</description>
</item>
<item>
<title>CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/cepi-and-samsung-biologics-collaborate-to-strengthen-outbreak-ready-vaccine-production-and-global-access</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/cepi-and-samsung-biologics-collaborate-to-strengthen-outbreak-ready-vaccine-production-and-global-access</guid>
<pubDate>Tue, 03 Feb 2026 13:00:00 GMT</pubDate>
<description>The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. The collaboration will see Samsung Biologics join CEPI's Vaccine Manufacturing Facility Network (VMFN) with the aim of accelerating the availability of protein-based vaccines and advancing equitable access to t</description>
</item>
<item>
<title>Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-receives-ecovadis-platinum-the-highest-sustainability-rating</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-receives-ecovadis-platinum-the-highest-sustainability-rating</guid>
<pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has received the EcoVadis' Platinum Sustainability Rating, the highest level of recognition for corporate sustainability performance.</description>
</item>
<item>
<title>Samsung Biologics reports fourth quarter and fiscal year 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-fourth-quarter-and-fiscal-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-fourth-quarter-and-fiscal-year-2025-financial-results</guid>
<pubDate>Wed, 21 Jan 2026 07:20:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), reported financial results for the fourth quarter and fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-expands-u-manufacturing-224300355</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-expands-u-manufacturing-224300355</guid>
<pubDate>Sun, 21 Dec 2025 22:43:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK (LSE/NYSE: GSK). This strategic move secures Samsung Biologics' first U.S.-based manufacturing site, a significant expansion of the company's global footprint and its long-term commitment to the U.S. market.</description>
</item>
<item>
<title>Samsung Biologics recognized as a global leader in water security</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-global-leader-233000880</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-recognized-global-leader-233000880</guid>
<pubDate>Wed, 10 Dec 2025 23:30:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that it has received from the Carbon Disclosure Project (CDP) an 'A' rating in Water Security.</description>
</item>
<item>
<title>Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-completes-spin-off-120000432</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-completes-spin-off-120000432</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS) today announced the completion of its spin-off of Samsung Bioepis, reinforcing its strategic focus and business specialization as a leading pure-play Contract Development and Manufacturing Organization (CDMO).</description>
</item>
<item>
<title>Newly Established Samsung Epis Holdings to Drive Growth for Samsung Bioepis and a New Subsidiary</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/newly-established-samsung-epis-holdings-to-drive-growth-for-samsung-bioepis-and-a-new-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/newly-established-samsung-epis-holdings-to-drive-growth-for-samsung-bioepis-and-a-new-subsidiary</guid>
<pubDate>Mon, 03 Nov 2025 02:17:00 GMT</pubDate>
<description>INCHEON, Korea, November 03, 2025--Samsung Epis Holdings announced its establishment as an investment holding company, following the spin-off of Samsung Bioepis from Samsung Biologics.</description>
</item>
<item>
<title>Samsung Biologics reports third quarter 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-third-quarter-065000449</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-third-quarter-065000449</guid>
<pubDate>Tue, 28 Oct 2025 06:50:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-introduces-optimized-manufacturing-110000602</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-introduces-optimized-manufacturing-110000602</guid>
<pubDate>Thu, 09 Oct 2025 11:00:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled ExellenS TM – an optimized manufacturing framework applied across the company's biomanufacturing network.</description>
</item>
<item>
<title>Samsung Biologics reports second quarter 2025 financial results</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-second-quarter-065400542</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-reports-second-quarter-065400542</guid>
<pubDate>Wed, 23 Jul 2025 06:54:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025.</description>
</item>
<item>
<title>Samsung Biologics launches drug screening services, Samsung Organoids</title>
<link>https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-launches-drug-screening-233000485</link>
<guid isPermaLink="true">https://6ix.com/company/samsung-biologics-co-ltd/news/samsung-biologics-launches-drug-screening-233000485</guid>
<pubDate>Sun, 15 Jun 2025 23:30:00 GMT</pubDate>
<description>Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced the launch of Samsung Organoids – advanced drug screening services to support clients in drug discovery and development.</description>
</item>
</channel>
</rss>